Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07438405

An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease

The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Thyroid Eye Disease Autoimmune Diseases Congenital, Hereditary, and Neonatal Diseases and Abnormalities Endocrine System Diseases Exophthalmos Eye Diseases Eye Diseases, Hereditary Genetic Diseases, Inborn Goiter Graves Disease Graves Ophthalmopathy Hyperthyroidism Immune System Diseases Orbital Diseases Thyroid Diseases

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Eb Group Spolka z ograniczona odpowiedzialnoscia, Warsaw, Poland

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  • Age ≥ 18 years at the time of signing informed consent for parent trial.
  • Moderate-to-severe TED at the time of enrollment in parent trial and does not require immediate surgical ophthalmological intervention and is not planning corrective surgery/irradiation during the rollover trial.
  • Any worsening in thyroid status should be corrected to maintain euthyroid status for the entire rollover trial.
  • Participants must use protocol-specified contraception during treatment and for an additional 6 months after the last dose of trial intervention.
  • Participants with TED who completed Amgen-sponsored clinical trial of AMG 732.

Exclusion criteria

  • Prior orbital irradiation or decompression in the study eye.
  • Prior adult strabismus surgery.
  • Use of any steroid (intravenous, oral, or injected) and steroid eye drops or other non-steroid immunosuppressive agent, monoclonal antibody except the trial drug in parent trial within a protocol-specified number of months prior to the first injection of study drug.
  • Glycated hemoglobin (HbA1c) > 6.5% and/or fasting glucose levels> 126 mg/dL (> 7 mmol/L) at screening.
  • Malignant condition in the past 5 years or major surgery within 8 weeks or plans to have an elective surgery from screening through end of study.
  • Active liver or kidney disfunction at screening.
  • Positive test for hepatitis B/C or Human immunodeficiency virus (HIV) serology at screening.
  • Known hypersensitivity to teprotumumab, AMG 732 or any other monoclonal antibody products.
  • Participants have had an adverse event that is considered related to AMG 732 which required study drug interruption/discontinuation in the parent study
  • Donated blood, or had significant blood loss, or received a transfusion of any blood or blood products within 60 days prior to day 1 dosing or received a plasma donation within 7 days prior to day 1 dosing.
  • Use of any steroid or other non-steroid immunosuppressive agent, monoclonal antibody, within 3 months prior to the first injection of study drug.
  • History or existing inflammatory bowel disease (ulcerative colitis or Crohn's disease).
  • Other protocol-defined inclusion/exclusion criteria apply.

Treatment and study plan

AMG 732

Drug

AMG 732 will be administered SC.

Primary outcomes

  1. Number of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who are Defined as Primary Nonresponders or Relapsed During the Safety Follow-up in the Parent Trial

    Time frame: Week 24

    Responders are defined as participants with a ≥ 2 mm reduction from baseline in the trial eye without deterioration (≥ 2 mm increase) of proptosis in the fellow eye.

Secondary outcomes

  1. Change from Baseline at Week 24 in Proptosis Measurement by an Exophthalmometer in the Trial Eye in Participants with TED who are Defined as Primary Nonresponders or Relapsed During the Safety Follow-up in the Parent Trial

    Time frame: Baseline and Week 24

  2. Number of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who had Relapse after Achieving Proptosis Response in the Parent Trial

    Time frame: Week 24

    Responders are defined as participants with a ≥ 2 mm reduction from baseline in the trial eye without deterioration (≥ 2 mm increase) of proptosis in the fellow eye.

  3. Change from Baseline at Week 24 in Proptosis Measurement by an Exophthalmometer in the Trial Eye in Participants with TED who had Relapse after Achieving Proptosis Response in the Parent Trial

    Time frame: Baseline and Week 24

  4. Number of Participants who are Proptosis Responders in the Trial Eye at Week 24 in Participants with TED who were Defined as Primary Nonresponders in the Parent Trial

    Time frame: Week 24

    Responders are defined as participants with a ≥ 2 mm reduction from baseline in the trial eye without deterioration (≥ 2 mm increase) of proptosis in the fellow eye.

  5. Change from Baseline at Week 24 in Proptosis Measurement by an Exophthalmometer in the Trial Eye in Participants with TED who were Defined as Primary Nonresponders in the Parent Trial

    Time frame: Baseline and Week 24

  6. Trough Concentration (Ctrough) of AMG 732

    Time frame: Baseline to Week 24

  7. Maximum Observed Concentration (Cmax) of AMG 732

    Time frame: Baseline to Week 24

  8. Time to Cmax (tmax) of AMG 732

    Time frame: Baseline to Week 24

  9. Area Under the Concentration-time Curve (AUC) Over the Dosing Interval of AMG 732

    Time frame: Baseline to Week 24

  10. Half-life (t1/2) of AMG 732

    Time frame: Baseline to Week 24

  11. Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESEAs), Adverse Events Leading to Investigational Product Discontinuation and Events of Interest (EOIs)

    Time frame: Up to Week 48

Study contacts

Contact information is provided by the study sponsor or research team.

Amgen Call Center

CONTACT

[email protected]

866-572-6436

Sponsors and collaborators

Lead sponsor

Amgen

Industry

Registry information

Official study title

An Open-label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-sponsored AMG 732 Studies and Are Primary Proptosis Non-responders or Who Relapsed During the Safety Follow-up

Acronym: HAZEL 401

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Feb 27, 2026
Registry last updated
Jul 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.